Identification of candidate biomarkers using the Experion™ automated electrophoresis system in serum samples from ovarian cancer patients

Kim,Ju  Hee; Kim,Yong-Wan; Kim,In-Wook; Park,Dong  Chun; Kim,Yong  Wook; Lee,Keun-Ho; Jang,Chun  Keun; Ahn,Woong  Shick

doi:10.3892/ijo.2013.1803

Identification of candidate biomarkers using the Experion™ automated electrophoresis system in serum samples from ovarian cancer patients

Authors:
- Ju Hee Kim
- Yong-Wan Kim
- In-Wook Kim
- Dong Chun Park
- Yong Wook Kim
- Keun-Ho Lee
- Chun Keun Jang
- Woong Shick Ahn
View Affiliations

Affiliations: Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul 130-040, Republic of Korea, Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul 130-040, Republic of Korea
Published online on: January 29, 2013 https://doi.org/10.3892/ijo.2013.1803
Pages: 1257-1262

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most common cause of disease-related death in women globally. Detection of ovarian cancer using new biomarkers is necessary for early diagnosis. To date, there have been no obvious biomarkers for ovarian cancer detection in the incipient stage. In this study, we discovered potential diagnostic serological biomarkers for ovarian cancer using the Experion™ automated electrophoresis system. Sera from 14 healthy women and 84 ovarian cancer patients at stages I- IV were applied to the Experion to compare the protein expression levels. To examine the protein expression pattern of Experion data, proteins in the samples were resolved using 10 and 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by silver staining. The candidate biomarkers elevated in ovarian cancer were purified and determined using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. α-2-macroglobulin (173.7 kDa), ceruloplasmin (147 kDa), inter-α-trypsin inhibitor family heavy chain-related protein (126 kDa), C-1 inhibitor (115.2 kDa) and hemoglobin α/β (14.4 kDa were overexpressed in the ovarian cancer sera. This study documents a novel way to measure ovarian cancer or cancer-related proteins for biomarkers using the Experion assay system, which should be easily adaptable for high-throughput diagnosis to establish databases of ovarian cancer for clinical applications.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
2	Visintin I, Feng Z, Longton G, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
3	Suh KS, Park SW, Castro A, et al: Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn. 10:1069–1083. 2010. View Article : Google Scholar : PubMed/NCBI
4	Bast RC Jr, Urban N, Shridhar V, et al: Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 107:61–97. 2002.PubMed/NCBI
5	Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin. 52:23–47. 2002. View Article : Google Scholar
6	Keyes K, Cox K, Treadway P, et al: An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res. 62:5597–5602. 2002.PubMed/NCBI
7	Keyes KA, Mann L, Cox K, et al: Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol. 51:321–327. 2003.PubMed/NCBI
8	Sasaroli D, Coukos G and Scholler N: Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med. 3:275–288. 2009. View Article : Google Scholar : PubMed/NCBI
9	Szekanecz E, Sandor Z, Antal-Szalmas P, et al: Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann NY Acad Sci. 1108:359–371. 2007. View Article : Google Scholar
10	Gupta D and Lis CG: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI
11	Scholler N and Urban N: CA125 in ovarian cancer. Biomark Med. 1:513–523. 2007. View Article : Google Scholar
12	Rice LW, Lage JM, Berkowitz RS, et al: Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol. 46:226–229. 1992. View Article : Google Scholar : PubMed/NCBI
13	Pearl ML, Yashar CM, Johnston CM, Reynolds RK and Roberts JA: Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol. 53:339–343. 1994. View Article : Google Scholar : PubMed/NCBI
14	Bast RC Jr, Badgwell D, Lu Z, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15(Suppl 3): 274–281. 2005. View Article : Google Scholar : PubMed/NCBI
15	Kitawaki J, Ishihara H, Koshiba H, et al: Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum Reprod. 20:1999–2003. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ye B, Cramer DW, Skates SJ, et al: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 9:2904–2911. 2003.
17	Raja FA, Hook JM and Ledermann JA: Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev. 38:662–672. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fleige S and Pfaffl MW: RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med. 27:126–139. 2006. View Article : Google Scholar : PubMed/NCBI
19	Park YD, Kim SY, Jang HS, et al: Towards a proteomic analysis of atopic dermatitis: a two-dimensional-polyacrylamide gel electrophoresis/mass spectrometric analysis of cultured patient-derived fibroblasts. Proteomics. 4:3446–3455. 2004. View Article : Google Scholar
20	Bahk YY, Kim SA, Kim JS, et al: Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics. 4:3299–3307. 2004.PubMed/NCBI
21	Gobom J, Nordhoff E, Mirgorodskaya E, Ekman R and Roepstorff P: Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom. 34:105–116. 1999. View Article : Google Scholar
22	Kim SY, Kim YS and Bahk YY: Proteome changes induced by expression of tumor suppressor PTEN. Mol Cells. 15:396–405. 2003.PubMed/NCBI
23	Armstrong PB: Proteases and protease inhibitors: a balance of activities in host-pathogen interaction. Immunobiology. 211:263–281. 2006. View Article : Google Scholar : PubMed/NCBI
24	Shield-Artin KL, Bailey MJ, Oliva K, et al: Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics. Proteomics Clin Appl. 6:170–181. 2012. View Article : Google Scholar
25	Samokyszyn VM, Miller DM, Reif DW and Aust SD: Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem. 264:21–26. 1989.PubMed/NCBI
26	Healy J and Tipton K: Ceruloplasmin and what it might do. J Neural Transm. 114:777–781. 2007. View Article : Google Scholar : PubMed/NCBI
27	Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI and Hashim OH: Can the acute-phase reactant proteins be used as cancer biomarkers? Int J Biol Markers. 25:1–11. 2010.PubMed/NCBI
28	Lee CM, Lo HW, Shao RP, et al: Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res. 64:1788–1793. 2004. View Article : Google Scholar : PubMed/NCBI
29	Negishi A, Ono M, Handa Y, et al: Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci. 100:514–519. 2009. View Article : Google Scholar : PubMed/NCBI
30	Choi-Miura NH: Novel human plasma proteins, IHRP (acute phase protein) and PHBP (serine protease), which bind to glycosaminoglycans. Curr Med Chem Cardiovasc Hematol Agents. 2:239–248. 2004. View Article : Google Scholar : PubMed/NCBI
31	Davis AE III, Mejia P and Lu F: Biological activities of C1 inhibitor. Mol Immunol. 45:4057–4063. 2008. View Article : Google Scholar : PubMed/NCBI
32	Maccio A, Madeddu C, Massa D, et al: Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 106:362–367. 2005. View Article : Google Scholar : PubMed/NCBI
33	Woong-Shick A, Sung-Pil P, Su-Mi B, et al: Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci. 96:197–201. 2005. View Article : Google Scholar : PubMed/NCBI
34	De Falco G and Giordano A: pRb2/p130: a new candidate for retinoblastoma tumor formation. Oncogene. 25:5333–5340. 2006.PubMed/NCBI
35	Schaffer BE, Park KS, Yiu G, et al: Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 70:3877–3883. 2010. View Article : Google Scholar : PubMed/NCBI
36	Ho VM, Schaffer BE, Karnezis AN, Park KS and Sage J: The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene. 28:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
37	Schweigert FJ and Sehouli J: Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res. 65:1114author reply 1114,. 2005.PubMed/NCBI
38	Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S and Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
39	Min HJ, Bae SM, Kwak SY, et al: Application of Experion™ assay system for discovery of ovarian cancer serum biomarkers. Korean J Obstet Gynecol. 50:751–759. 2007.